Skip to main content

Fine Particular Matter Linked to Increase in Breast Cancer Risk

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 12, 2023 -- Fine particulate matter (PM2.5) is associated with an increased risk for breast cancer, specifically estrogen receptor-positive (ER+) breast cancer, according to a study published online Sept. 11 in the Journal of the National Cancer Institute.

Alexandra J. White, Ph.D., from the National Institute of Environmental Health Sciences in Research Triangle Park, North Carolina, and colleagues estimated annual average PM2.5 concentrations for a five-year historical period 10 years prior to enrollment of women in a prospective cohort study. The adjusted hazard ratios for the association between a 10-µg/m3 increase in PM2.5 and breast cancer incidence were estimated overall and by ER status and catchment area.

A total of 15,870 breast cancer cases were identified with follow-up through 2017. The researchers observed a significant association for a 10-µg/m3 increase in PM2.5 with overall breast cancer incidence (hazard ratio, 1.08; 95 percent confidence interval, 1.02 to 1.13). The association was significant for ER+ tumors (hazard ratio, 1.10; 95 percent confidence interval, 1.04 to 1.17) but was not seen for ER− tumors (hazard ratio, 0.97; 95 percent confidence interval, 0.84 to 1.13). Across the catchment areas, the overall breast cancer hazard ratios (95 percent confidence intervals) were >1, ranging from 1.04 (0.68 to 1.57) in Louisiana to 1.26 (0.96 to 1.64) in North Carolina.

"We observed an 8 percent increase in breast cancer incidence for living in areas with higher PM2.5 exposure. Although this is a relatively modest increase, these findings are significant given that air pollution is a ubiquitous exposure that impacts almost everyone," White said in a statement. "These findings add to a growing body of literature suggesting that air pollution is related to breast cancer."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.